NCT07214779 2026-04-16
MAESTRA 2
Incyte Corporation
Phase 3 Recruiting
Clinical Trials
82 trialsNCT06172296 2026-04-14
Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma
National Cancer Institute (NCI)
Phase 3 Recruiting
NCT06459180 2026-04-13
TroFuse-020
Merck Sharp & Dohme LLC
Phase 3 Recruiting
NCT06500026 2026-04-13
A Study Comparing BL-B01D1 With Topotecan in Patients With Recurrent Small Cell Lung Cancer
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 3 Active not recruiting
NCT07418749 2026-04-06
A Study of SHR-A2102 Versus Investigator's Choice of Chemotherapy in Patients With Platinum-based Chemotherapy and PD-(L)1 Inhibitor Treatment Failed Recurrent or Metastatic Cervical Cancer
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Phase 3 Recruiting
NCT07213804 2026-03-20
FRAmework-01
Eli Lilly and Company
Phase 3 Recruiting
NCT06801834 2026-03-19
EVOKE-SCLC-04
Gilead Sciences
Phase 3 Recruiting
NCT07286266 2026-03-19
A Study to Investigate GSK5733584 Compared With Chemotherapy in Participants With Platinum-resistant Ovarian Cancer (BEHOLD-Ovarian01)
GlaxoSmithKline
Phase 3 Not yet recruiting
NCT05153239 2026-03-09
Clinical Trial of Lurbinectedin as Single-agent or in Combination With Irinotecan Versus Topotecan or Irinotecan in Patients With Relapsed Small-cell Lung Cancer (LAGOON)
PharmaMar
Phase 3 Active not recruiting
NCT07099898 2026-03-06
A Study of GSK5764227 in Participants With Relapsed Small Cell Lung Cancer (SCLC)
GlaxoSmithKline
Phase 3 Recruiting
NCT06619236 2026-03-03
RAINFOL-02
Genmab
Phase 3 Active not recruiting
NCT06203210 2026-03-02
IDeate-Lung02
Daiichi Sankyo
Phase 3 Recruiting
NCT03126916 2026-02-27
Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL)
Children's Oncology Group
Phase 3 Recruiting
NCT04697628 2026-02-24
innovaTV 301
Seagen Inc.
Phase 3 Completed
NCT06647953 2026-02-24
Testing a Standardized Approach to Surgery and Chemotherapy for Type I Pleuropulmonary Blastoma or the Addition of an Anti-cancer Drug, Topotecan, to the Usual Treatment for Types II and III Pleuropulmonary Blastoma
Children's Oncology Group
Phase 3 Recruiting
NCT07365241 2026-01-26
A Study to Evaluate Adverse Events and Change in Disease Activity of Intravenous ABBV-706 Versus Standard of Care in Adult Participants With Relapsed/Refractory Small Cell Lung Cancer
AbbVie
Phase 3 Not yet recruiting
NCT01231906 2026-01-23
Combination Chemotherapy in Treating Patients With Non-Metastatic Extracranial Ewing Sarcoma
Children's Oncology Group
Phase 3 Completed
NCT07218809 2026-01-16
TREVI-OC-01
AstraZeneca
Phase 3 Recruiting
NCT05740566 2026-01-05
DeLLphi-304
Amgen
Phase 3 Active not recruiting
NCT07189455 2026-01-05
Study Comparing ZG006 With Investigator-Selected Chemotherapy in Participants With Relapsed Small Cell Lung Cancer
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Phase 3 Recruiting
NCT06855069 2025-12-17
HS-20089 for Injection in Patients With Platinum-Resistant Recurrent Epithelial Ovarian Cancer
Hansoh BioMedical R&D Company
Phase 3 Recruiting
NCT04908787 2025-09-11
A Phase III Study of BD0801 Combined With Chemotherapy in Recurrent, Platinum-resistant Epithelial Ovarian Cancer
Jiangsu Simcere Pharmaceutical Co., Ltd.
Phase 3 Completed
NCT00186888 2025-09-04
Study of Treatment for Patients With Cancer of the Eye -Retinoblastoma
St. Jude Children's Research Hospital
Phase 3 Completed
NCT05092360 2025-08-28
ARTISTRY-7
Mural Oncology, Inc
Phase 3 Terminated
NCT04209855 2025-08-27
MIRASOL
AbbVie
Phase 3 Completed
NCT06994195 2025-08-17
A Study Comparing BL-B01D1 With the Investigator's Choice of Chemotherapy in Patients With Platinum-resistant Recurrent Epithelial Ovarian Cancer
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 3 Recruiting
NCT06954246 2025-06-18
A Study of MHB088C Injection Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer
Qilu Pharmaceutical Co., Ltd.
Phase 3 Recruiting
NCT06828354 2025-03-24
A Study of SHR-A1811 in Subjects With Ovarian Cancer
Jiangsu HengRui Medicine Co., Ltd.
Phase 3 Recruiting
NCT03088813 2025-02-19
RESILIENT
Ipsen
Phase 3 Completed
NCT06612151 2025-02-11
A Phase III Study of YL201 in Relapsed Small Cell Lung Cancer
MediLink Therapeutics (Suzhou) Co., Ltd.
Phase 3 Recruiting
NCT06751485 2024-12-31
JSKN003 in Platinum-Resistant, Relapsed Epithelial Ovarian Cancer
Jiangsu Alphamab Biopharmaceuticals Co., Ltd
Phase 3 Not yet recruiting
NCT06616532 2024-12-19
PM8002 in Combination With Paclitaxel Compared With Chemotherapy as Second-line Treatment in Small Cell Lung Cancer
Biotheus Inc.
Phase 3 Recruiting
NCT06496048 2024-12-12
Lurbinectedin or in Combination with Irinotecan Versus Topotecan in Patients with Relapsed SCLC
Luye Pharma Group Ltd.
Phase 3 Recruiting
NCT06498479 2024-10-16
ARTEMIS-008：HS-20093 Compared With Topotecan in Subjects With Relapsed Small Cell Lung Cancer
Hansoh BioMedical R&D Company
Phase 3 Recruiting
NCT06581380 2024-09-03
JK-1201I Compared with Topotecan in Patients with Relapsed Extensive Stage Small Cell Lung Cancer
JenKem Technology Co., Ltd.
Phase 3 Not yet recruiting
NCT06394492 2024-08-09
SHR-A1921 for Injection in Patients With Platinum-Resistant Recurrent Epithelial Ovarian Cancer
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Phase 3 Recruiting
NCT06128837 2024-03-15
Study of LY01610 in Patients With Recurrent Small Cell Lung Cancer
Luye Pharma Group Ltd.
Phase 3 Recruiting
NCT00657878 2023-11-13
MITO-8
National Cancer Institute, Naples
Phase 3 Unknown
NCT02584478 2023-11-08
AL3818
Advenchen Laboratories, LLC
Phase 3 Unknown
NCT02481830 2023-07-27
CheckMate331
Bristol-Myers Squibb
Phase 3 Completed
NCT04943627 2022-10-05
Balstilimab Versus Investigator Choice Chemotherapy in Patients With Recurrent Cervical Cancer (BRAVA)
Agenus Inc.
Phase 3 Withdrawn
NCT00976911 2022-06-21
AURELIA: A Study of Avastin (Bevacizumab) Added to Chemotherapy in Patients With Platinum-resistant Ovarian Cancer
Hoffmann-La Roche
Phase 3 Completed
NCT00567567 2022-04-28
Comparing Two Different Myeloablation Therapies in Treating Young Patients Who Are Undergoing a Stem Cell Transplant for High-Risk Neuroblastoma
Children's Oncology Group
Phase 3 Completed
NCT02566993 2021-10-28
ATLANTIS
PharmaMar
Phase 3 Completed
NCT04679064 2021-08-27
NItCHE-MITO33
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Phase 3 Unknown
NCT02903004 2021-08-25
MITO23
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Phase 3 Completed
NCT00499616 2021-07-06
Combination Chemotherapy and Surgery With or Without Isotretinoin in Treating Young Patients With Neuroblastoma
Children's Oncology Group
Phase 3 Completed
NCT04799002 2021-03-16
Topotecan and Melphalan for Retinoblastoma
Sun Yat-sen University
Phase 3 Recruiting
NCT03061812 2021-02-23
TAHOE
AbbVie
Phase 3 Completed
NCT02631876 2020-10-14
FORWARD I
ImmunoGen, Inc.
Phase 3 Completed